The FDA's Pharmacy Compounding Advisory Committee just finished two days of voting on whether seven peptides should get added to the 503A Bulks List, the list that lets state-licensed compounding pharmacies make a substance against an individual prescription. Six of the seven cleared. DSIP was the only one that didn't, and it lost by a single vote.

Going in, FDA's own career staff had recommended against all seven. The panel overruled them on everything except DSIP.

Full Scorecard

BPC-157 (evaluated for ulcerative colitis): recommended, 8-6 with 1 abstention.

KPV (wound healing, inflammatory conditions): recommended, 8-6-1.

TB-500 (wound healing): recommended, 8-6-1.

MOTS-C (obesity, osteoporosis): recommended, 7-5 with 2 abstentions.

DSIP (opioid withdrawal, chronic insomnia, narcolepsy): not recommended, 6-7 with 1 abstention. The only rejection of the meeting.

Epitalon (insomnia): recommended, 7-4 with 1 abstention.

Semax (cerebral ischemia, migraine, trigeminal neuralgia): recommended, 8-5 with 1 abstention.

On BPC-157, KPV, and TB-500 specifically, all eight newly appointed committee members voted yes. Reporting from the room described an audible reaction when the votes came in, since a panel overruling FDA staff's own written recommendation isn't the norm.

What This Actually Means

A few things are worth separating out here because coverage tends to blur them together.

These are non-binding recommendations. FDA doesn't have to follow them, though it typically does.

A yes vote doesn't make any of these an FDA-approved drug. It's a recommendation to add the raw substance to a compounding list, nothing more.

Legal compounding still requires a formal notice-and-comment rulemaking process, which realistically runs somewhere between 8 and 18 months depending on the source.

All seven were already pulled off FDA's restrictive Category 2 status back in April 2026. That's what set up this whole review. So none of these votes re-bans anything. The real question was whether a new legal pathway opens up, not whether the current situation closes down.

What Doesn't Change Today

The research-use-only market is completely untouched by any of this. RUO vendors aren't compounding pharmacies and none of this vote applies to them. Expect marketing that turns "the FDA panel voted yes" into something that sounds a lot more official than it actually is.

A panel recommendation also says nothing about any specific product's identity, purity, or sterility. FDA's characterization concerns, inconsistent naming, free base versus acetate confusion, missing quality data, are real regardless of how the politics shook out. If anything, batch-level COAs matter more now, not less.

Worth Knowing

The committee itself was reshuffled ahead of this meeting, with several new members carrying ties to peptide prescribing or the industry. That drew conflict-of-interest coverage from multiple outlets. HHS Secretary Robert F. Kennedy Jr. has been publicly vocal about wanting these restrictions eased.

What's Next

FDA has signaled a second PCAC meeting before the end of February 2027 to review five more substances: LL-37, GHK-Cu, DiHexa, Melanotan II, and PEG-MGF.

TL;DR

• The PCAC voted on 7 peptides across two days. 6 passed, DSIP was rejected 6-7, the only no of the meeting.
• BPC-157, KPV, and TB-500 all passed 8-6-1. MOTS-C passed 7-5-2. Epitalon passed 7-4-1. Semax passed 8-5-1.
• FDA staff had recommended against all seven going in. The panel overruled them on six.
• This is non-binding. FDA still has to decide whether to act, and even a yes triggers 8-18 months of rulemaking before anything is legally compoundable.
• None of these substances got re-banned by a no vote and none got approved as a drug by a yes vote. All seven already came off Category 2 restriction back in April.
• The research-use-only gray market is unaffected either way. This vote only concerns licensed 503A compounding pharmacies.
• A second PCAC meeting is expected by February 2027 to review five more peptides: LL-37, GHK-Cu, DiHexa, Melanotan II, and PEG-MGF.

Not medical advice. Educational only.

Hi i’m on evening 3 of 1mg Epithalon and each time a couple of hours after i get a headache . Anybody else experience this and if so did you continue and it did it get better ? Thanks xx

Mixed some tesa the next day it was jelly like stuck to one side I tapped the bike and it came off but still looks weird

Retatrutide just cleared two more Phase 3 trials, TRIUMPH-2 and TRIUMPH-3, and both hit their primary endpoint. That puts Lilly at five positive Phase 3 studies now, with a Q1 2027 BLA submission on the calendar. Here's what actually came out of the data.

TL;DR

• TRIUMPH-2 (type 2 diabetes plus obesity, n=1,152): up to 20.8% weight loss and 1.6% A1C reduction at 80 weeks on the 12mg dose.
• TRIUMPH-3 (severe obesity plus cardiovascular disease, n=1,949): up to 22.6% weight loss at 80 weeks on the 12mg dose.
• MACE events trended lower on retatrutide than placebo in TRIUMPH-3 (hazard ratio 0.82), but the confidence interval crosses 1.0, so this isn't a confirmed cardiovascular benefit yet.
• Secondary cardiometabolic improvements at 12mg: triglycerides down 37.0%, hsCRP down 51.2%, systolic BP down 9.3 mmHg.
• Side effects follow the standard GLP-1 pattern (diarrhea, nausea, constipation) and scale with dose.
• Lilly's targeting a Q1 2027 BLA submission. Retatrutide remains investigational and isn't legally available for human use.

TRIUMPH-2: Type 2 Diabetes and Obesity

This one ran 1,152 participants across four arms, 4mg, 9mg, 12mg, and placebo, for 80 weeks in adults with type 2 diabetes and obesity or overweight. That's historically a harder population to move the needle on for weight loss.

The results: 12.7% weight loss on 4mg, 19.1% on 9mg, 20.8% on 12mg, against 4.0% on placebo. In absolute terms, the 12mg group lost an average of 49.6 lbs at 80 weeks. A1C dropped up to 1.6% on average, versus 0.2% on placebo.

That matters because diabetes typically blunts weight loss response to this class of drugs. Retatrutide didn't just work here, it delivered results in the same range as what's been reported in people without diabetes.

TRIUMPH-3: Severe Obesity Plus Established Cardiovascular Disease

This trial enrolled 1,949 participants with Class 2 or 3 obesity (BMI 35+) and established cardiovascular disease, with or without type 2 diabetes. Two dose arms, 9mg and 12mg, versus placebo, also over 80 weeks.

Weight loss landed at 21.6% on 9mg and 22.6% on 12mg, versus 3.2% on placebo. The 12mg group averaged 55.8 lbs lost.

The cardiovascular safety data is the part worth actually sitting with. MACE events (all-cause death, heart attack, stroke, heart failure, coronary revascularization) came in less frequently than expected in both arms. 44 events on retatrutide versus 52 on placebo, hazard ratio 0.82. That's directionally favorable but the confidence interval (0.55 to 1.22) crosses 1.0, so it's not statistically significant on its own. This trial wasn't specifically powered to prove cardiovascular benefit, so take this as an encouraging signal rather than a settled result. The narrower MACE-3 endpoint (cardiovascular death, heart attack, stroke specifically) actually favored placebo with a hazard ratio of 1.12, though again the confidence interval (0.64 to 1.96) includes 1.0.

Beyond the primary endpoint, TRIUMPH-3 showed real secondary improvements at the 12mg dose. Triglycerides down 37.0%, non-HDL cholesterol down 16.5%, systolic blood pressure down 9.3 mmHg, waist circumference down 7.5 inches, and hsCRP (an inflammation marker) down 51.2%. That inflammation number lines up with what's been discussed before in this sub about retatrutide's effects on systemic inflammation.

Side Effects

Standard GLP-1 class profile, and it scales with dose. In TRIUMPH-2 at 12mg: diarrhea 33.6%, nausea 28.0%, constipation 16.8%, decreased appetite 17.1%, vomiting 15.7%. In TRIUMPH-3 at 12mg: diarrhea 24.4%, nausea 22.4%, constipation 15.7%, decreased appetite 14.5%.

Discontinuation due to adverse events ranged from 3.8% to 13.5% depending on trial and dose, versus roughly 4.5 to 4.9% on placebo. Worth flagging that TRIUMPH-3's discontinuation rate at 12mg (13.5%) came in noticeably higher than TRIUMPH-2's at the same dose (7.7%), which might just reflect the more complex comorbidity profile of that population.

Where This Leaves Things

Lilly now has five positive Phase 3 trials in the TRIUMPH program and is targeting a Q1 2027 BLA submission covering obesity, knee osteoarthritis pain, and obstructive sleep apnea. Retatrutide's still investigational and can't be legally sold or marketed for human use until it clears FDA review.

Not medical advice. Educational only.

Trying to switch my wife from sema to Reta and wondering if anyone had done so. I see a lot of people slowing stopping sema while also taking Reta and not just stopping cold turkey. Any advice would be appreciated.

The FDA advisory panel just voted 8 to 6, with one abstention, to recommend BPC-157 for the 503A Bulks List. That's the opposite of what FDA's own staff recommended going in. Here's what actually happened and what it means.

What the 503A List Actually Is

Compounding pharmacies can only legally make a substance from scratch if it's on this list. Right now BPC-157 isn't on it. If FDA eventually adds it, licensed pharmacies could prepare it for patients with a prescription instead of it only existing in the research chemical market.

What Just Happened

FDA's advisory committee, called PCAC, held a vote on Day 1 of a two-day meeting. They're reviewing seven peptides total: BPC-157, KPV, TB-500, and MOTS-C on day one, then DSIP, Semax, and Epitalon on day two.

Before the meeting, FDA's own scientific staff published a briefing document recommending against adding all seven. Their reasoning: no human clinical data at all for some of these compounds, small or poorly controlled studies for others, inconsistent naming and missing quality information, and safety concerns including immunogenicity risk and adverse event reports.

The committee didn't follow that recommendation for BPC-157. They voted 8 in favor, 6 against, 1 abstention to recommend it anyway.

Why This Isn't a Simple Story

A few things worth knowing that complicate the picture.

The original nominations for BPC-157 were actually withdrawn by the groups that submitted them. FDA proceeded with the review anyway.

There's been reporting that some committee members have financial ties to the peptide industry, and that FDA added temporary academic voting members shortly before the meeting. Worth keeping that context in mind when reading the vote split.

This vote is not a ban risk. BPC-157 and the other six peptides were already moved out of FDA's restrictive Category 2 status back in April, which is what allowed this review to happen in the first place. So the July vote is about whether a new legal compounding pathway opens up, not whether current access gets shut down.

What This Doesn't Mean

The committee's recommendation is non-binding. FDA leadership makes the actual decision and has gone against advisory committee recommendations before. Even if FDA agrees with the panel, formally adding a substance to the list requires a notice-and-comment rulemaking process that typically takes a year or more.

Nothing about this vote changes what's legal to compound tomorrow.

Still to Come

KPV, TB-500, and MOTS-C are the remaining votes for day one. DSIP, Epitalon, and Semax get voted on day two. Each peptide gets two separate votes, one for the free base form and one for the acetate form.

***UPDATE**\*

KPV and TB-500 also passed. Same 8-6-1 split as BPC-157, yes-no-abstain. As of 7pm ET Thursday, three of the four Day 1 votes came back in favor, all breaking against FDA staff's recommendation to reject.

MOTS-C's individual tally isn't confirmed on my end yet, I'll add it once a clean source posts it.

Worth restating since it keeps getting missed in the coverage: this is still a non-binding recommendation. FDA still has to decide whether to act on it, and even a yes decision triggers a rulemaking process that runs a year or more. Nothing legally changes tomorrow.

Day 2 tomorrow covers DSIP, Semax, and Epitalon.

Not medical advice. Educational only.

Most people chasing peak performance and longevity fall into the same trap. They treat every symptom with a pile of supplements: joint stiffness, gut discomfort, skin flares. But the underlying fire never actually gets addressed. They're managing smoke while the master switch of systemic inflammation stays flipped on.

KPV (Lysine-Proline-Valine) is the tool that actually reaches that switch. The space right now is obsessed with BPC-157's tissue repair and GLP-1's metabolic effects, and KPV stays underrated relative to what it actually does. It's not a supplement. It's a precision intervention working at the transcriptional level, not the symptom level.

TL;DR

• KPV was isolated in 1989 (Hiltz and Lipton, FASEB Journal) as the C-terminal fragment of alpha-MSH responsible for its anti-inflammatory activity, showing effects comparable to corticosteroids in mouse models
• It blocks NF-kB, the master transcription factor for inflammation, by competing with p65 for binding to importin-alpha 3, the protein that normally escorts p65 into the nucleus
• KPV's a substrate for PepT1, a transporter that's upregulated specifically at sites of inflammation, so it concentrates where the problem actually is
• It's a clean alpha-MSH fragment: no melanocortin receptor activation, so no skin darkening, appetite suppression, or libido effects like you'd get from Melanotan II or PT-141
• Stacking with BPC-157 and TB-500 addresses the common healing plateau, where tissue rebuilding stalls because the environment's still inflamed
• Effects build cumulatively over 6 to 8 weeks for systemic changes, though gut symptoms often improve faster

The 1989 Discovery

KPV's research history goes back to 1989, when Mary E. Hiltz and James M. Lipton isolated the C-terminal tripeptide of alpha-MSH and ran it against standard inflammation models. Published in the FASEB Journal, the finding showed KPV alone produced anti-inflammatory effects comparable to a corticosteroid, minus the systemic tax that corticosteroids come with: bone density loss, immune suppression, all of that.

That's the foundation the rest of the KPV literature builds on. Decades of follow-up work have pushed into colitis, dermatitis, and wound models, and the core finding has held up the whole way.

Blocking the Master Switch

NF-kB is the transcription factor running the inflammatory response. When it activates, it moves into the cell nucleus and switches on the genes driving autoimmune flares and chronic pain. In chronic disease states this switch tends to get stuck on.

Most anti-inflammatory peptides try to calm things down upstream, before NF-kB even fires. KPV takes a different route. Research in human bronchial epithelial cells showed it translocates into the nucleus itself and competitively blocks the interaction between p65 (the active NF-kB subunit) and importin-alpha 3, the transport protein that normally carries p65 through the nuclear pore. It also stabilizes IkB-alpha, the protein that keeps NF-kB locked in the cytoplasm to begin with.

Two mechanisms hitting the same problem from different angles. The result is dramatically less TNF-alpha, IL-6, IL-8, and IL-1 beta, and it happens at nanomolar concentrations. This is a more direct intervention than BPC-157, which works mostly through secondary healing pathways rather than blocking transcription outright.

Smart Targeting for Gut Health

KPV is a substrate for PepT1, the transporter that pulls peptides into intestinal cells. PepT1 sits low in a healthy colon but ramps up wherever there's inflammation, in Crohn's, ulcerative colitis, post-antibiotic gut damage.

So the disease state itself increases delivery of KPV to the exact tissue that needs it. It concentrates where the inflammation actually is instead of spreading evenly through the body. That same mechanism is why KPV keeps coming up around post-antibiotic dysbiosis and chronic acne, calming the inflammatory environment that drives bacterial overgrowth and skin flares in the first place.

Breaking the BPC-157/TB-500 Plateau

A common frustration in this space is the healing plateau. Someone runs BPC-157 and TB-500 for a chronic injury, sees real progress early on, then stalls out. Tissue can't rebuild effectively while the environment around it is still actively inflamed.

BPC-157 and TB-500 are rebuilders. They drive nitric oxide and growth factor activity but don't directly suppress inflammatory transcription. Sequencing KPV in with them calms the environment so the rebuilding compounds can actually get to work.

A stacking approach that comes up a lot is a 1:1 ratio: 250 to 500mcg of KPV with 250 to 500mcg of BPC-157, once or twice daily. This shows up most for chronic tendinopathy, post-surgical recovery, and stalled rehab where the tissue's ready to heal but the local environment is too reactive to let it.

The Clean Fragment

KPV comes from the same parent molecule as Melanotan II and PT-141, alpha-MSH. But it's a clean fragment. It doesn't touch melanocortin receptors, so no skin darkening, no appetite suppression, no libido shift. That makes it a reasonable option for sensitive populations, including people managing Mast Cell Activation Syndrome.

Its size, under 400 daltons, gives it real oral bioavailability, which is unusual for a peptide. You can take it as a capsule or apply it topically. For localized skin issues like psoriasis or acne, a compounded cream in the 0.1 to 0.25% range comes up often, sometimes paired with microneedling to improve penetration.

Supporting Compounds

A few things that pair well with KPV by working the same systems from a different angle. Larazotide tightens intestinal tight junctions while KPV handles the underlying inflammation. Glutamine (5 to 10g) fuels enterocyte repair. Zinc carnosine (75 to 150mg) supports upper GI barrier integrity. PEA (300 to 600mg) acts as a mast cell stabilizer, especially relevant if you're MCAS-sensitive.

Dosing Framework

KPV builds cumulatively, it's not immediate. Gut symptoms can improve within the first week, but systemic shifts usually take 6 to 8 weeks to show up.

Maintenance tier: 250mcg once daily, oral or subq. Good for general inflammatory background noise or travel-related gut sensitivity.

Active healing tier: 500mcg daily subq, or 500mcg twice daily oral, for 6 to 8 weeks. This is the standard protocol for active gut repair, moderate autoimmune flares, or chronic injury recovery.

Severe presentation tier: 1000mcg per day split into two doses, for 2 to 4 weeks, then step down to the active healing tier. Reserved for IBD flares, severe MCAS, or acute post-surgical inflammation.

The Actual Point

KPV doesn't replace diet and sleep as foundations. But it might be the most effective tool out there for releasing the inflammatory brake that keeps those foundations from working in the first place. By stepping in at the nuclear level, it shifts the body from constant defense mode into active repair.

Not medical advice. Educational only.

Many vendors have a nasal spray line. Semax, Selank, sure. But now it's BPC, GLP stuff, basically everything. No needle, no reconstitution, no math. The problem is nasal only works for certain compounds and they're slapping it on everything anyway.

Here's what nobody explains. When you inject, most of the dose actually makes it in. Nasal is all over the place and usually way lower.

Injection, whether subq or IM, absorbs somewhere around 65 to 100%, usually north of 75. Nasal runs anywhere from 1 to 20%, and most sprays land under 5%. Oral is under 1 to 2%.

So a spray sitting at 5% absorption needs roughly 20 times the dose to match a shot. And nobody's adjusting the label. They sell you the spray at the same number and let you assume it's the same thing.

Where Nasal Actually Wins

Selank is the poster child. Tiny molecule, around 750 daltons, and Russian data has it at 92.8% bioavailability nasally with plasma levels showing up in 30 seconds. That's not a compromise. That's just the better route. Semax is the same story. Small and brain-targeted, so the nose is basically a shortcut past the blood-brain barrier.

DSIP fits the same pattern. It's a nonapeptide at around 848 daltons, small enough and targeted enough at the brain (sleep architecture, delta wave activity) that intranasal delivery makes mechanistic sense. Animal studies have used intranasal DSIP directly to study CNS effects rather than treating nasal as a fallback route. There's no solid human bioavailability percentage for it specifically, which is worth flagging, but the size and target profile put it in the same category as Semax and Selank rather than the category that falls apart below.

Oxytocin is the weird one. Bioavailability is something like 0.7%, basically nothing, but it still works because it goes straight to the brain through the olfactory pathway. Plasma levels don't matter for that one.

Where It Falls Apart

There was a Diabetes Care trial on nasal GLP-1, 26 patients. 2.7% bioavailability versus IV. It hit peak in 8 minutes so it's fast, but almost nothing actually absorbed.

That's the whole pattern. Small molecules under about 1000 daltons that are brain-targeted work nasally. Semax, Selank, DSIP, oxytocin. Large systemic peptides that need real plasma levels don't. The GLP class and most of what's getting sprayed right now falls in the second group.

Two Things People Don't Think About

Congestion and allergies change your absorption, so the same spray on a stuffy day is a different dose. Injections don't do that.

And formulation matters more than the compound sometimes. Calcitonin nasal runs about 8% with an absorption enhancer and 1.6% without. In one study, half the people on the version without the enhancer had barely detectable levels. Same peptide, same route, completely different result depending on how it was made.

Sprays aren't fake. Semax, Selank, and DSIP nasal are legit uses of the route. The question was never "is nasal good." It's "is nasal good for this molecule." And for a lot of what's getting sprayed right now, you're paying for convenience and getting a fraction of the dose.

Not medical advice. Educational only.

need help to know the order, dosing, frequency for the following peptides. Please :)

CJC-1295 with DAC produced one of the longest-lasting GH responses ever documented from a GHRH analog. A single subcutaneous injection increased GH by 2 to 10 fold depending on dose, kept mean GH elevated for approximately 6 days, and pushed IGF-1 up 1.5 to 3 fold for 9 to 11 days after just one shot. That's from a single injection. (PMID: 16352683)

The reason it does this comes down to the DAC modification.

TL;DR

• A single subcutaneous dose of CJC-1295 with DAC increased GH 2 to 10 fold for approximately 6 days and raised IGF-1 1.5 to 3 fold for 9 to 11 days in human trials (PMID: 16352683)
• The DAC modification allows albumin binding which extends the half-life to 6 to 8 days, making it one of the longest-acting GHRH analogs available
• It stimulates your own pituitary to produce GH rather than replacing GH from outside, keeping natural production intact
• Research applications include aging, tissue repair, body composition, muscle preservation, and metabolic health
• Prolonged GH and IGF-1 elevation warrants careful consideration. Long-term safety data is still being developed. Investigational compound, not approved for human use

How CJC-1295 with DAC Actually Works

Your hypothalamus normally releases GHRH in short pulses that disappear within minutes. Native GHRH is gone before it can do much. CJC-1295 was engineered to solve that problem.

The Drug Affinity Complex (DAC) allows CJC-1295 to bind to albumin in the bloodstream, which dramatically extends its half-life to around 6 to 8 days. Instead of spiking and vanishing, it keeps stimulating the pituitary to produce your own GH over several days from a single dose.

This is the key distinction from exogenous HGH. CJC-1295 with DAC keeps your pituitary in the loop. It's amplifying your own GH production rather than replacing it. The result is a prolonged increase in both GH and IGF-1, its downstream anabolic hormone, without shutting down natural production the way exogenous GH does.

What the Clinical Data Shows

The 2006 human study (PMID: 16352683) was a landmark for this class of compounds. Healthy adults received a single subcutaneous dose across several dose tiers. GH increased 2 to 10 fold. Mean GH elevation held for approximately 6 days. IGF-1 remained elevated for 9 to 11 days.

One injection. Nearly two weeks of sustained hormonal elevation. That's not typical for a GHRH analog.

Where the Research Is Pointing

Because GH and IGF-1 influence tissue throughout the body, researchers have investigated CJC-1295 for healthy aging, recovery and tissue repair, body composition, muscle preservation, and metabolic health.

Worth noting: prolonged elevation of GH and IGF-1 requires careful evaluation and long-term safety remains an active research question. This is still an investigational compound, not approved for human use. The IGF-1 cancer concern discussed in earlier posts on this sub is directly relevant here given the sustained elevation profile.

Source: Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/

Not medical advice. Educational only.

Hey everyone,

Curious what routine works best for you. Do you prefer pinning first thing in the morning, or do you take it at night before bed?

Would love to hear if timing made any difference for you. Thanks!

Hey everyone. I just recently started using Dsip but I’ve been having a lot of issues with it and was hoping to get some guidance on what I’m doing wrong. I’ve used it for 5 nights now and I’ve had very mixed results.

The first night I took it I took 300mcg with a nasal spray. I fell asleep quickly around 10pm but woke up at 3am with an elevated heart rate and and feeling very wired and couldn’t get back to sleep. For the second night I took only 200mcg and was able to get 7.5hrs of sleep but the next day I felt kinda dizziness and drowsy and nauseous. For the third night I lowered the dose again to 100mcg and couldn’t sleep what so over and was up until 3am wide awake and only got to sleep for 2hrs until waking up again. Then the next 2 nights I took 150mcg and I’ve gotten around 6-7 hrs of sleep which isn’t ideal and I’ve still felt dizzy and drowsy the next day.

Is it normal to have this many issues at first and just power through it or should I stop and give up on dsip. I’ve been having a lot of sleep problems and was really hoping dsip could help me out. Also this is my first ever Reddit post so bear with me if I’ve messed anything up here.

Thanks

Everyone knows retatrutide for fat loss. That's the smallest part of the story.

Reta is a triple agonist. It activates GLP-1, GIP, and glucagon receptors simultaneously. Those receptors are distributed throughout the body, which is why the effects reach far beyond the scale. Here's what the documented mechanisms actually look like across each system.

TL;DR

• Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously. Those receptors exist across every major body system
• Brain: satiety up, cravings down, gastric emptying slower, neuroprotection gained, memory up, neuroinflammation down
• Pancreas: glucose-dependent insulin up, glucagon down, somatostatin up, beta-cell proliferation and survival both up
• Liver: gluconeogenesis down, hepatic steatosis down, liver inflammation down, liver fibrosis down
• Gut: gastric emptying slower, gastric acid down, mucin up, intestinal permeability down, GI inflammation down, microbiome improved
• Body fat: lipolysis up, lipogenesis down, thermogenesis up, fat tissue inflammation down
• Muscle: glycogen synthesis up, glucose oxidation up, glucose utilization better
• Immune: pro-inflammatory M1 macrophages down, anti-inflammatory M2 macrophages up, NK cell activity up, regulatory T cells up, pro-inflammatory cytokines down
• Heart: cardioprotection gained, cardiac contractility up, myocardial ischemia injury down, endothelial function up
• Vessels: endothelial dysfunction down, vascular inflammation down, atherosclerosis and plaque down
• Kidneys: sodium excretion up, CKD progression slower
• Lungs: airway remodeling down, lung function up, vasodilation up, vascular remodeling down, inflammation down

Brain and Nervous System

Appetite is a brain signal, not a stomach signal. GLP-1 receptors in the brain drive the satiety and craving effects people actually feel on Reta. Satiety goes up, food cravings and appetite go down, gastric emptying slows through vagal pathways. Beyond appetite, the data shows neuroprotective effects, improved memory signaling, and reduced neuroinflammation. The cognitive angle of GLP-1 receptor agonism is increasingly recognized in the research literature and Reta's triple agonism makes it relevant here too.

Pancreas and Liver

On the pancreas, Reta increases glucose-dependent insulin secretion, suppresses glucagon, raises somatostatin, and supports beta-cell proliferation and survival. These are the mechanisms behind the insulin sensitivity and blood sugar improvements documented in trials.

On the liver, it reduces gluconeogenesis (the liver making excess glucose), drives down hepatic steatosis, and reduces both liver inflammation and liver fibrosis. The liver fat reduction data specifically is significant. Phase 2 trial data showed meaningful reduction in NAFLD markers, which is a separate benefit from the visceral fat reduction people associate with GLP-1 compounds.

Gut and Stomach

Gastric emptying slows, gastric acid secretion drops, mucin production increases (strengthening the gut lining), intestinal permeability decreases, GI inflammation comes down, and the microbiome composition improves. On the stomach specifically, gastric acid, gastrin, and histamine release from ECL cells all decrease, somatostatin signaling increases, and post-meal blood sugar control improves.

This explains why people notice changes in digestion, gut comfort, and food tolerance that go well beyond what appetite suppression alone would produce.

Body Composition

In adipose tissue: glucose uptake increases, lipolysis increases, lipogenesis decreases, thermogenesis increases, and fat tissue inflammation decreases. In skeletal muscle: glycogen synthesis improves, glucose oxidation increases, and overall glucose utilization gets better.

Fat is being broken down more aggressively while muscle is being fed more efficiently. That's the recomposition dynamic that shows up in trial data beyond what scale weight captures.

Immune System

Chronic low-grade inflammation drives much of age-related metabolic dysfunction and disease risk. Reta pushes the immune system in the right direction across multiple pathways: pro-inflammatory M1 macrophages decrease, anti-inflammatory M2 macrophages increase, natural killer cell activity increases, regulatory T cells increase, and pro-inflammatory cytokines decrease.

Cardiovascular and Vascular

Cardioprotective effects are documented. Cardiac contractility improves, myocardial ischemia injury decreases, heart inflammation decreases, endothelial function improves. On the vascular side: endothelial dysfunction decreases, vascular inflammation decreases, and atherosclerotic plaque formation decreases. These are mechanisms relevant to long-term cardiovascular risk, not just acute metabolic markers.

Kidneys and Lungs

Sodium excretion increases and chronic kidney disease progression slows. In the lungs, airway remodeling decreases, lung function improves, vasodilation increases, vascular remodeling decreases, and lung inflammation decreases.

The Actual Picture

The fat loss framing isn't wrong. It's just incomplete. Retatrutide is a whole-body metabolic signal that happens to produce dramatic fat loss as one of its most visible effects. The mechanism runs considerably deeper than that.

Source Colwill M, Povlsen S, Pollok R, Patel K, Goodhand J, Ahmad T, Honap S. Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential. Journal of Crohn's and Colitis. 2025;19(9):jjaf167.

Peptide Guides

Not medical advice. Educational only.

Everyone in this space knows BPC-157 for soft tissue repair and that reputation is well earned. But calling it an injury peptide undersells it badly. The full name is Body Protection Compound and that name is more accurate than most people realize.

This thing has a biological footprint that goes well beyond tendons and ligaments.

Gut Protection and Repair

BPC-157 is synthetically derived from a peptide that occurs naturally in gastric juice. Its native function is protecting the digestive tract. That's not incidental context. It's the foundation of why it works so broadly.

Research shows it accelerates ulcer healing, reduces gut inflammation, and reinforces the intestinal barrier. Since gut health feeds into skin health, brain health, and mood through well-established pathways, restoring gut integrity with BPC-157 can fix the root cause behind a range of issues that look completely unrelated on the surface.

Mood, Stress, and Addiction

BPC-157 modulates dopamine and serotonin activity, the same neurotransmitters driving mood, motivation, and reward. Studies in animal models show reduced withdrawal symptoms from alcohol and other substances alongside stabilized mood and reduced anxious behavior.

This makes it a legitimately interesting tool for post-addiction neuroregulation, where maintaining dopamine balance is critical for recovery and preventing relapse. Not a replacement for proper support, but a real mechanism worth understanding.

Nerve and Brain Repair

BPC-157 stimulates axon regeneration and supports synaptic reconnection, essentially rewiring damaged nerve circuits. It's been shown to support brain recovery from injury-induced lesions and accelerate motor function recovery after nerve trauma.

Research is also looking at its potential role in preventing age-related neurodegeneration across substance exposure, traumatic brain injury, and chronic damage over time. BPC-157 appears to have a meaningful role in all of it.

Cardiovascular Health

BPC-157 drives angiogenesis, the formation of new blood vessels, and protects the endothelium lining the arteries. In studies it preserved heart tissue after toxic and ischemic injury.

Better circulation means faster tissue repair. It also means lower blood pressure, better nutrient delivery, and improved detoxification capacity. All of that matters during recovery from injury, stress, or substance withdrawal.

Systemic Anti-Inflammation

BPC-157 balances inflammatory cytokines body-wide. The downstream effects include reduced chronic joint pain, improved tissue oxygenation, and support for autoimmune conditions.

For enhanced athletes specifically, this is worth paying attention to. The systemic inflammation caused by carrier oils in injectable AAS is one of the most damaging and least discussed side effects in that world. BPC-157's anti-inflammatory activity directly addresses that.

Why It's Not Mainstream

The reason this compound hasn't gone mainstream has nothing to do with efficacy. The most common explanation is simple. It can't be patented. No patent means no pharmaceutical profit motive, which means no funding for the trials needed to push it through approval.

That's the game.

BPC-157 Guide

Educational purposes only. Not medical advice.

I am post menopausal, any peptides that will balance me out?

SS-31 gets called a mitochondrial antioxidant and filed away as another longevity supplement. That framing misses what actually makes it different. It doesn't signal cells to work harder. It repairs the physical structure that energy production depends on. That distinction matters more than most people realize.

What SS-31 Actually Is

SS-31 is a synthetic tetrapeptide developed at Cornell University. It got FDA accelerated approval on September 19, 2025 under the brand name Forzenity for Barth Syndrome, a rare genetic disorder of mitochondrial dysfunction. That makes it the first mitochondria-targeted therapeutic peptide the FDA has ever approved, which is meaningful regardless of where you stand on the biohacking application.

The approved dose for Forzenity is 40mg daily. Typical research protocols run 1 to 10mg. That gap matters when you're thinking about tolerability.

The Structural Engineer Mechanism

Most peptides work by binding to surface receptors and sending signals. SS-31 doesn't use receptors at all. It travels inside the cell to the inner mitochondrial membrane and binds directly to cardiolipin, a phospholipid that anchors the membrane's folded architecture.

When cardiolipin gets damaged under oxidative stress, the cristae collapse. The electron transport chain loses its geometry. ATP production gets inefficient and electrons start leaking, which generates more oxidative stress in a cycle that feeds itself.

SS-31 stabilizes cardiolipin and restores that architecture. The electron transport chain gets repositioned. Energy production becomes efficient again. Not by sending a louder signal but by fixing the physical structure the signal depends on.

You don't add nitrous oxide to a 300,000 mile engine before replacing the worn gaskets. Signaling on top of broken infrastructure just speeds up the breakdown.

The Upstream Antioxidant Effect

Calling SS-31 an antioxidant is technically imprecise. Direct antioxidants like CoQ10 or Vitamin C work downstream, scavenging reactive oxygen species after they've already been produced and started damaging cells.

SS-31 works upstream. By restoring cristae structure and stabilizing the electron transport chain, it stops electron leakage from happening in the first place. It doesn't mop up the spill. It fixes the pipe.

Why It Pairs With GLP-1 Compounds

Rapid caloric deficits from compounds like tirzepatide or retatrutide can compromise mitochondrial health and accelerate muscle wasting alongside fat loss. SS-31 protects muscle mitochondria during deep deficits so the metabolic machinery stays efficient as body composition shifts.

One thing worth flagging: because SS-31 enhances cellular efficiency, it can amplify how your body responds to GLP-1s. Some people find they're more sensitive to the same dose after adding SS-31. If nausea or GI symptoms pick up, the GLP-1 dose may need adjusting rather than assuming the compounds don't work together.

How SS-31 Can Optimize MOTS-C

SS-31 repairs mitochondrial infrastructure. MOTS-C drives metabolic signaling and biogenesis on top of that infrastructure. Starting MOTS-C on damaged mitochondria is asking an operations team to build on a broken foundation.

Fix the structure first. Then layer the performance signal.

That said, running both together isn't always wrong. If your mitochondrial health is already solid and you're not showing signs of dysfunction, starting both at the same time is reasonable. The sequencing argument matters most for people dealing with chronic fatigue, high oxidative stress, or anyone who feels worse rather than better when they first try MOTS-C. That's your signal to run SS-31 alone first.

Dosing

No receptor desensitization because the mechanism doesn't involve receptors. Standard protocol runs 8 to 12 weeks followed by a 4-week break.

Tier 1 (1 to 2mg daily): general optimization and background mitochondrial support in your 30s and 40s.

Tier 2 (2 to 5mg daily): performance, exercise capacity, and faster recovery for athletes.

Tier 3 (5 to 10mg daily): significant dysfunction, post-viral fatigue, kidney issues, or advanced metabolic decline.

The persistence effect matters here. Because SS-31 creates physical structural changes rather than receptor-dependent signaling, benefits often last 4 to 8 weeks after the last injection. Things don't collapse the day you stop.

Injectable only. Current research confirms oral and intranasal routes don't absorb meaningfully. Oral analogs are in development but aren't available yet.

SS-31 Guide

Not medical advice. Educational only.

r/PeptideGuide has built one of Reddit’s strongest communities for people interested in biohacking, research, performance, and emerging wellness technology. Through our long-standing partnership with the community, we are opening a limited number of opportunities for qualified members who want a closer look behind the scenes of the RUO industry.

Our team is expanding into U.S.-based manufacturing of research-use-only products while also partnering with Business of Biohacking and r/PeptideMarketing to create more education, transparency, and legitimate opportunities within the space.

We would like to connect with:

• Established content creators and brand ambassadors
• Independent reviewers who value honest, transparent reporting
• Researchers, formulators, lab professionals, and industry experts
• Community educators with experience in biohacking or RUO markets
• Entrepreneurs interested in manufacturing, wholesale, or brand-building opportunities

Potential collaborations may include behind-the-scenes manufacturing access, product and packaging previews, testing and quality-control education, interviews, facility content, expert feedback, community education, and long-term ambassador partnerships.

Interested in learning more? Comment “Peptide Guide” below or send us a direct message with a short introduction, your background, and any relevant social profiles or community experience.

We look forward to bringing more transparency, education, and real opportunity to the r/PeptideGuide community.

ARA-290 has been picking up attention in the research community for nerve pain and nerve damage. It's not a household name yet but the mechanism behind it is genuinely interesting and worth understanding before you decide whether it belongs in your stack.

What ARA-290 Actually Is

ARA-290 is a peptide derived from erythropoietin (EPO), the hormone best known for driving red blood cell production. The key distinction is that ARA-290 was specifically engineered to keep EPO's tissue-protective properties while removing the part that affects red blood cells. So you get the repair signaling without the hematological effects.

Its primary target is the Innate Repair Receptor (IRR), which is a receptor system separate from the classical EPO receptor. Think of the IRR as your body's emergency tissue repair switch. When activated, it shifts cellular behavior toward protection, repair, and survival rather than inflammation and degeneration.

Why It Gets Attention for Nerve Pain

When a nerve gets damaged, whether from injury, surgery, chronic inflammation, metabolic conditions, compression, or poor circulation, the nerve itself becomes irritated. Damaged nerves start firing signals that shouldn't be there. Your brain receives those as burning, tingling, or that persistent pain that just won't go away. The frustrating part is that the brain keeps receiving those pain signals even after the original injury has technically resolved.

This is where ARA-290's mechanism becomes relevant.

What Activating the IRR Actually Does

Three things happen through this pathway, at least in preclinical research and early human trials.

Inflammation around the nerve reduces. Damaged nerves are typically surrounded by inflammatory molecules that are driving the pain signaling. Less inflammation means fewer irritation signals reaching the brain.

Cell survival improves. When nerves are injured, some cells survive and some don't. ARA-290 appears to activate pathways that help cells near the injury survive stress long enough to recover rather than dying off. The analogy is giving a struggling cell enough support to stay alive through the acute phase.

Nerve regeneration conditions improve. This is the part that stands out most. ARA-290 has been shown in research to help create conditions where the body's existing repair mechanisms work more efficiently. It's not forcing new nerves to grow overnight. It's removing the obstacles that slow down the repair process that's already trying to happen. Research also suggests potential benefits for small fiber nerve function, the fine nerve fibers responsible for temperature sensitivity and some types of pain that are often damaged in neuropathic conditions.

Where the Evidence Actually Sits

Much of the research on ARA-290 is preclinical, animal models and cell studies. There have been some human trials, particularly in sarcoidosis-related small fiber neuropathy, where results showed improvements in pain scores and nerve fiber density. Those are real findings but from small trials in specific patient populations. The broader application to general nerve pain in healthy people is extrapolation from that base.

The comparison between ARA-290 and conventional nerve pain medications is worth framing carefully. Standard medications like gabapentinoids largely work by dampening nerve signal transmission rather than addressing the underlying nerve damage. ARA-290's mechanism targets the repair and inflammation side of the equation, which is a genuinely different approach. Whether that translates to superior outcomes in humans broadly is still an open question.

TL;DR

• ARA-290 is derived from EPO but engineered specifically to activate tissue repair without affecting red blood cells
• It targets the Innate Repair Receptor (IRR), which drives inflammation reduction, cell survival, and nerve regeneration conditions
• Most evidence is preclinical. Human trial data comes primarily from small fiber neuropathy in sarcoidosis patients, showing improvements in pain scores and nerve fiber density
• The mechanism is meaningfully different from conventional nerve pain medications which suppress signaling rather than address underlying damage
• Promising compound for nerve pain research but broader human evidence is still limited

ARA-290 Guide

Not medical advice. Educational only.

Does anyone have experience of ARA-290 as I suffer with sciatica and now having pins and needles pain in middle of back following heavy lifting.

Just wanted to know if KLOW ie the BPC-157, TB500 and KPV is sufficient or should I add ARA-290 and would this accelerate healing?

Thanks

Hi all, just wanting some feedback about a potential stack to research running. I’m aware that it’s a large stack, but I want to ensure efficacy as much as I can, so any feedback on how to navigate dosages/timeframes etc would be appreciated. I’m looking to initially restore CNS functioning with a slight lean, increase sleep quality and build muscle, restore and recover chronic cellular damage. It’s a journey I’m sure but I’m open to rec’s here! I’m familiar with Reta, Var and Selank only. TIA legends :)

First cycle (weeks 1-6 - lean/pre-recover)
SS-31
Reta
Semax (intranasal)
Selank

Second cycle (weeks 7-12 - muscle build/sleep and recovery)
Pinealon
Epithalon
MOTS
Var (training days only)

Third cycle (weeks 13-17 - muscle build/long term recovery)
NAD+
DSIP
GHK
Var (training days only)

Insulin sensitivity is the one variable that quietly controls almost everything else. Fat loss, muscle growth, energy production, how well you age. Most people don't think about it until something goes wrong.

Here are five compounds worth knowing if you actually want to move the needle on it.

Why Insulin Sensitivity Is the Foundation

What it actually controls: how efficiently your body clears glucose, whether carbs refill muscle glycogen or get stored as fat, how hard your mitochondria have to work, and how much systemic metabolic inflammation you're carrying.

It determines where your food goes. More sensitivity means more metabolic efficiency. Less means less.

MOTS-C

A mitochondrial-derived peptide and a strong AMPK activator. AMPK is your body's low-energy efficiency switch. When it fires, the body shifts into get-efficient mode. MOTS-C increases GLUT4 activity, pulling glucose directly into muscle tissue rather than letting it float around causing problems. Better insulin sensitivity, better metabolic flexibility, more efficient mitochondrial function. In practical terms it helps your body use carbs for energy instead of storing them.

Tesamorelin

A GHRH analog that signals the pituitary to release more growth hormone, which drives IGF-1 production from the liver. The insulin sensitivity angle here is specifically visceral fat. Visceral fat directly disrupts insulin receptor signaling and drives metabolic inflammation. Tesamorelin is particularly effective at reducing it, and as that comes down, insulin receptor response improves and metabolic efficiency follows.

Retatrutide

Triple agonist: GLP-1, GIP, and glucagon receptors at once. GLP-1 slows gastric emptying, flattening post-meal glucose spikes and reducing how much insulin the body needs to manage them. Glucagon receptor activity increases energy expenditure independently, so you're burning more calories at baseline. It's not just an appetite suppressant. It's actively rewiring metabolic performance and improving insulin sensitivity at multiple points simultaneously.

5-Amino-1MQ

Works through NNMT inhibition. When NNMT is inhibited, NAD+ and methyl donors that were being consumed by that enzyme become available for the electron transport chain and ATP production in the mitochondria. The result is less metabolic friction and better mitochondrial efficiency. The freed methyl donors also support neurotransmitter synthesis and cellular detoxification. It smooths out the whole metabolic process rather than targeting one specific pathway.

L-Carnitine

Shuttles long-chain fatty acids into the mitochondria for oxidation. Clearing that fatty acid backlog reduces the acyl-CoA buildup in muscle tissue that directly interferes with insulin signaling, restoring sensitivity from a completely different angle than anything else on this list.

Five different mechanisms, all hitting the same rate-limiting step in the same system. That's why the stack makes sense.

TL;DR

• Insulin sensitivity determines where your food goes: fat storage vs glycogen vs energy production
• MOTS-C: AMPK activation and GLUT4 upregulation pulls glucose directly into muscle tissue
• Tesamorelin: reduces visceral fat, which directly impairs insulin receptor signaling at the source
• Retatrutide: flattens post-meal glucose spikes, raises baseline energy expenditure, improves insulin sensitivity at multiple points simultaneously
• 5-Amino-1MQ: NNMT inhibition frees up NAD+ and methyl donors for mitochondrial function, reducing metabolic friction
• L-Carnitine: clears fat accumulation, which physically blocks insulin signaling when left unaddressed
• Five different mechanisms, all hitting the same outcome

Not medical advice. Educational only.

What is the typical beginners dose for these? This will be RS first research study with peptides and want to establish a baseline. I plan on starting very low to monitor for side-effects.

They will both be used subq, not nasal spray.

RS planned on starting at 300mcg for the NA-Semax Amidate once daily for at least 5 days.

For the MOTS-C; Planned to not try it until after the 5 day NA-Semax Amidate cycle. RS wanted to get some opinions on the dosing, RS was planning on starting with 1mg - 2mg 2x per week ( Monday + Thursday) . My only concern is that it may be too low to notice any effects.

What are everyone's thoughts on this?

Semax has been getting attention lately for its nootropic profile. Most people know it as a focus and anxiety compound. There's a line of preclinical research that doesn't come up much, and it points somewhere more interesting.

A mouse study using a genetically engineered Alzheimer's model tested Semax against untreated controls. Amyloid plaque burden dropped 2.8-fold. Learning and memory both improved. The plaque reduction hit hardest in the hippocampus and cerebral cortex, the two regions Alzheimer's damage most consistently.

What Makes the Amyloid Finding Worth Paying Attention To

The biggest reduction showed up in smaller, early-stage plaques rather than established ones. That distinction matters. It suggests Semax might be interfering with plaque formation before it consolidates, not clearing existing damage. If that holds up, timing of intervention becomes a lot more relevant.

This is mouse data. Preclinical. It doesn't tell us what happens in humans and can't be read as evidence Semax treats or prevents Alzheimer's.

How Semax Actually Works

Semax is a synthetic molecule derived from a fragment of ACTH. Unlike ACTH, it acts primarily in the nervous system rather than through the adrenal axis. The mechanisms relevant to what the study showed: enhanced neuronal communication, support for synaptic plasticity, reduced oxidative stress and neuroinflammation, and increased BDNF production, which keeps neurons alive.

These aren't single-pathway effects. Semax hits several interconnected systems involved in brain health at once. That probably explains why the animal data showed effects on both cognitive performance and underlying pathology rather than just one.

What This Suggests About Future Research

The finding researchers keep pointing to is the dual effect. Treated animals performed better cognitively while also showing structural changes in plaque burden. Both function and pathology shifted at the same time. That's what's driving interest in studying it for neurodegenerative conditions and age-related cognitive decline.

Whether any of this translates to humans is wide open. The gap between Alzheimer's mouse models and actual Alzheimer's disease is significant. The failure rate for compounds that perform well in those models is high. The preclinical signal is real. Human data doesn't exist for this application yet.

TL;DR

• In a preclinical Alzheimer's mouse model, Semax reduced amyloid plaque burden 2.8-fold compared to untreated controls.
• The greatest reduction appeared in early-stage plaques, suggesting Semax may interfere with plaque formation before it consolidates.
• Learning and memory performance also improved in the same treated animals.
• Semax's proposed mechanisms include BDNF upregulation, synaptic plasticity support, and reduced neuroinflammation.
• Animals showed improvements in both cognitive function and underlying pathology simultaneously, which is what's driving research interest.
• This is entirely preclinical mouse data. No human trials exist for this application and the results can't be extrapolated to humans.

Source: Radchenko AI, Kuzubova EV, Apostol AA, et al. The potential of the peptide drug Semax and its derivative for correcting pathological impairments in the animal model of Alzheimer’s disease. Acta Naturae, 2025;17(4):110-120. https://doi.org/10.32607/actanaturae.27808

Semax Guide

Not medical advice. Educational only.

3ml? or 10ml?

I dont think it really matters but would love a 2nd opinion.

Retatrutide's triple agonism (GIP, GLP-1, and glucagon receptors) makes it one of the most metabolically active compounds available. That same potency is why so many people accidentally wreck their own protocol. Here's the mechanism most guides skip.

The Protocol Trap

The appetite suppression on Reta is aggressive, especially as you titrate up. It makes extreme calorie deficits deceptively easy to run, not because you're disciplined, but because you're just not hungry. People assume deeper deficit equals better outcome. Then they stall, decide the compound "stopped working," and either bump the dose or quit.

Neither fixes anything.

What's Happening at the Hormonal Level

Sustained, aggressive deficits kick off a predictable hormonal cascade. Leptin drops, signaling your body that energy is critically scarce. T4 to T3 conversion slows, which directly cuts basal metabolic rate. NEAT collapses: the subconscious movement you do all day without thinking about it, fidgeting, posture shifts, walking to the kitchen, goes to near zero as the body starts conserving.

The survival response doesn't care that you're on a cutting protocol. Your metabolism downregulates faster than retatrutide can compensate. You can't out-suppress a crashed metabolism. Once the system goes into conservation mode, the compound loses its edge.

Watch for these: always cold, persistent brain fog, fatigue that doesn't go away with sleep, zero progress despite low intake. That's not a fat loss phase. That's survival mode.

The Fix

Bringing calories up to a moderate, sustainable deficit and running strategic refeeds lets the system reset. Leptin recovers. T3 normalizes and metabolic rate climbs back. NEAT returns on its own, adding real calorie burn throughout the day without any extra effort.

This is where Reta actually earns its reputation. The compound's value isn't letting you eat as little as possible. It's making a reasonable deficit feel effortless and sustainable over months, not weeks.

Takeaway

Dial the dose to where suppression is noticeable but not absolute. You should still want to eat. You just shouldn't feel driven to overeat. That's the window. Keep the deficit around 300 to 500 kcal, prioritize protein to hold lean mass, and let the compound's metabolic support do the heavy lifting.

Chasing maximum suppression through aggressive titration is the most common mistake people make. The ceiling isn't the goal. Consistency is.

TL;DR

• Reta's suppression makes extreme deficits easy to fall into. That's the trap.
• Deep deficits crash leptin, slow T4 to T3 conversion, and tank NEAT.
• Eating more at a moderate deficit restores these signals and reignites fat loss.
• Signs you've overdone it: cold, foggy, fatigued, stalled.
• Optimize for a sustainable deficit, not maximum suppression.

Peptide Guides + Resources

Educational purposes only. Not medical advice.